公开(公告)号：US11111276B2

公开(公告)日：2021-09-07

申请号：US16597850

申请日：2019-10-10

Applicant: Academia Sinica

Inventor： Han-Chung Wu ,  Chung-Tao Tang

IPC: C07K14/005 ,  A61K39/39 ,  C12N7/00 ,  A61K39/12 ,  C07K16/10 ,  G01N33/569 ,  A61K39/00

Abstract: Isolated mutant dengue virus E protein variants are disclosed. The variant comprises an amino acid sequence that is at least 80% identical to SEQ ID NO: 1 and has one or more amino acid residue substitutions at position corresponding to Asn8 (N8), Arg9 (R9), Val12 (V 12) and/or Glu13 (E13). The variant may comprise an amino acid sequence that is at least 90% identical to the SEQ ID NO: 1 and lack an infection-enhancing antibody-binding motif comprising the amino acid sequence of SEQ ID NO: 28 at domain I. An isolated nucleic acid sequence encoding the variant, a plasmid expressing the variant, a plasmid expressing a virus-like particle comprising the variant, a DNA vaccine, and a method of detecting the presence of a dengue virus in a biological sample are also disclosed.

公开(公告)号：US10118969B2

公开(公告)日：2018-11-06

申请号：US15011544

申请日：2016-01-30

Applicant: Academia Sinica

Inventor： Chi-Huey Wong ,  Chung-Yi Wu ,  Che Ma ,  Han-Chung Wu

IPC: C12N9/24 ,  C07K16/30 ,  C07K16/28 ,  A61K45/06 ,  C07K16/10 ,  C07K16/32 ,  C07K16/18 ,  C12P21/00

Abstract: The present disclosure relates to compositions and methods of use comprising antibodies or binding fragments thereof further comprising universal Fc glycoforms.

公开(公告)号：US20150344551A1

公开(公告)日：2015-12-03

申请号：US14599174

申请日：2015-01-16

Applicant: Academia Sinica

Inventor： Chi-Huey Wong ,  Tsui-Ling Hsu ,  Yi-Wei Lou ,  Chih-Wei Lin ,  Shih-Chi Yeh ,  Chung-Yi Wu ,  Han-Chung Wu

IPC: C07K16/18 ,  G01N33/574

CPC classification number: C07K16/18 ,  A61K2039/505 ,  C07K16/3053 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/734 ,  C07K2317/92 ,  G01N33/57407 ,  G01N33/57492 ,  G01N2800/52

Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, lung, breast, mouse, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervix, ovary, and/or prostate cancer.

Abstract translation: 本文公开了包含与SSEA-4结合的抗体或其抗原结合片段的药物组合物及其使用方法。 使用的方法包括但不限于癌症治疗和诊断。 本公开的抗体可以结合某些癌细胞表面。 本文公开的抗体的示例性靶标可以包括癌，例如脑，肺，乳腺，小鼠，食管，胃，肝，胆管，胰腺，结肠，肾，子宫颈，卵巢和/或前列腺癌中的那些。

公开(公告)号：US20190085062A1

公开(公告)日：2019-03-21

申请号：US15989860

申请日：2018-05-25

Applicant: Academia Sinica

Inventor： Chi-Huey Wong ,  Tsui-Ling Hsu ,  Yi-Wei Lou ,  Chih-Wei Lin ,  Shih-Chi Yeh ,  Chung-Yi Wu ,  Han-Chung Wu

IPC: C07K16/18 ,  G01N33/574

Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, lung, breast, mouse, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervix, ovary, and/or prostate cancer.

公开(公告)号：US09387257B2

公开(公告)日：2016-07-12

申请号：US14599291

申请日：2015-01-16

Applicant: Academia Sinica

Inventor： Han-Chung Wu ,  Yi-Hsuan Chi

IPC: A61K38/16 ,  C07K5/00 ,  A61K47/48 ,  A61K31/704 ,  G01N33/574

CPC classification number: A61K47/48246 ,  A61K31/704 ,  A61K47/48815 ,  A61K47/64 ,  A61K47/6911 ,  G01N33/57423 ,  G01N2458/00

Abstract: A conjugate is disclosed. The conjugate comprises (a) an isolated or a synthetic targeting peptide of less than 15 amino acid residues in length, comprising an amino acid sequence having at least 90% identity to a sequence selected from the group consisting of SEQ ID NOs: 1-8; and (b) a component conjugated to the targeting peptide, the component being selected from the group consisting of a drug delivery vehicle, an anti-cancer drug, a micelle, a nanoparticle, a liposome, a polymer, a lipid, an oligonucleotide, a peptide, a polypeptide, a protein, a cell, an imaging agent, and a labeling agent. Methods of treating lung cancer and detecting lung cancer cells are also disclosed.

Abstract translation: 公开了缀合物。 缀合物包含（a）长度小于15个氨基酸残基的分离或合成的靶向肽，其包含与选自SEQ ID NO：1-8的序列具有至少90％同一性的氨基酸序列 ; 和（b）与靶向肽缀合的组分，该组分选自药物递送载体，抗癌药物，胶束，纳米颗粒，脂质体，聚合物，脂质，寡核苷酸， 肽，多肽，蛋白质，细胞，成像剂和标记试剂。 还公开了治疗肺癌和检测肺癌细胞的方法。

公开(公告)号：US09187558B2

公开(公告)日：2015-11-17

申请号：US14381362

申请日：2013-03-01

Applicant: ACADEMIA SINICA

Inventor： Han-Chung Wu ,  Mei-Ying Liao ,  Cheng-Wei Lin

IPC: A61K39/395 ,  C07K16/18 ,  C07K16/30 ,  G01N33/574 ,  A61K39/00

CPC classification number: C07K16/18 ,  A61K2039/505 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/574

Abstract: An isolated monoclonal antibody or an antigen-binding fragment thereof is disclosed. The antibody or the antigen-binding fragment is characterized by: (a) having a specific binding affinity to epithelial cell adhesion molecule (EpCAM) comprising the amino acid sequence of SEQ ID NO: 1; (b) having a specific binding affinity to cancer cells expressing EpCAM said cancer cells being selected from the group consisting of oral cancer cells, nasopharyngeal cancer cells (NPC), colorectal cancer cells, and ovarian cancer cells; and (c) having no binding affinity to human umbilical vein endothelial cell (HUVEC) and normal nasal mucosal epithelia (NNM). Also disclosed is an isolated monoclonal antibody or an antigen-binding fragment thereof that has a specific binding affinity to an epitope within the sequence of KPEGALQNNDGLYDPDCDE (SEQ ID NO: 63) located within the EGF-like domain II of epithelial cell adhesion molecule (EpCAM). Methods of using the same are also disclosed.

Abstract translation: 公开了分离的单克隆抗体或其抗原结合片段。 抗体或抗原结合片段的特征在于：（a）对包含SEQ ID NO：1的氨基酸序列的上皮细胞粘附分子（EpCAM）具有特异性结合亲和力; （b）对表达EpCAM的癌细胞具有特异性结合亲和力，所述癌细胞选自口腔癌细胞，鼻咽癌细胞（NPC），结肠直肠癌细胞和卵巢癌细胞; 和（c）对人脐静脉内皮细胞（HUVEC）和正常鼻粘膜上皮细胞（NNM）没有结合亲和力。 还公开了与位于上皮细胞粘附分子（EpCAM）的EGF样结构域II内的KPEGALQNNDGLYDPDCDE（SEQ ID NO：63）的序列内的表位具有特异性结合亲和力的分离的单克隆抗体或其抗原结合片段 ）。 还公开了使用该方法的方法。

公开(公告)号：US08969530B2

公开(公告)日：2015-03-03

申请号：US13644311

申请日：2012-10-04

Applicant: Academia Sinica

Inventor： Han-Chung Wu ,  Kuo-Hua Tung

IPC: C07K16/00 ,  C12P21/08 ,  G01N33/53 ,  A61K39/395 ,  A61K39/00 ,  C07K16/18 ,  C07K16/30

CPC classification number: C07K16/18 ,  C07K16/303 ,  C07K2317/73

Abstract: A purified monoclonal antibody, or an. antigen-binding portion thereof, which specifically binds to human clathrin heavy chain (CHC) is disclosed. The antibody, or antigen-binding portion, thereof, exhibits at least one, two, three, four, five, six, seven, or all eight of the following properties: (a) specifically binds to pancreatic adenocarcinoma cells; (b) binding to the cell surface and cytosol of cancer cells and tumor blood vessels; (c) internalized by CHC-expressing cells; (d) inhibiting tumor growth, invasion ability, migration, and angiogenesis; (e) inducing apoptosis in cancer cells and human umbilical vein endothelial cells; (f) inhibiting tumor growth and tumor blood vessels in pancreatic cancer in vivo; (g) suppressing epidermal growth factor, transferrin, and VEGF internalizations by cancer cells; and (h) suppressing hypoxia-inducible factor-1α expression and vascular endothelial growth factor secretion. Methods for inhibiting tumor cell growth and/or angiogenesis, and detecting cancer in a subject is also disclosed.

Abstract translation: 纯化的单克隆抗体，或 公开了与人网格蛋白重链（CHC）特异性结合的抗原结合部分。 抗体或其抗原结合部分显示出以下性质中的至少一种，二种，三种，四种，五种，六种，七种或全部八种：（a）特异性结合胰腺腺癌细胞; （b）结合癌细胞和肿瘤血管的细胞表面和细胞溶质; （c）通过表达CHC的细胞内化; （d）抑制肿瘤生长，侵袭能力，迁移和血管生成; （e）诱导癌细胞和人脐静脉内皮细胞凋亡; （f）体内抑制胰腺癌肿瘤生长和肿瘤血管; （g）抑制癌细胞的表皮生长因子，转铁蛋白和VEGF内化; 和（h）抑制低氧诱导因子-1α表达和血管内皮生长因子分泌。 还公开了抑制肿瘤细胞生长和/或血管发生以及检测受试者中的癌症的方法。